Clinical Trial Update: A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients [Phase 3]

View source ↗

Summary

A Phase 3b trial of EB-101 for recessive dystrophic epidermolysis bullosa (DEB) in new and previously EB-101 treated patients is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• EB-101

Snippet

Sponsor: Abeona Therapeutics, Inc | Conditions: Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Status: ACTIVE_NOT_RECRUITING